75601-36-4

Upstream product

• 108-67-8 1,3,5-trimethyl-benzene 
• 5779-95-3 3,5-dimethylbenzaldehyde 

Downstream Products

• 22445-42-7 3,5-dimethylbenzonitrile 
• 1040748-41-1 N,N'-(ethane-1,2-diylidene)bis[(3,5-dimethylphenyl)methanamine oxide] 

Relevant academic research and scientific papers

One-Pot Regioselective Synthesis of 7-Bromo-2H-Benzo[b][1,4]Oxazin-3(4H)-One Linked Isoxazole Hybrids as Anti-Cancer Agents and Their Molecular Docking Studies

Abstract: Regioselective synthesis of some novel 7-bromo-2H-benzo[b][1,4]oxazin-3(4H)-one linked isoxazole hybrids via copper(I) catalyzed one-pot reaction of various aromatic aldehydes with 7-bromo-4-(prop-2-yn-1-yl)-2H-benzo[b][1,4]oxazin-3(4H)-one was developed. The structures of the compounds that are synthesized are confirmed by 1H NMR, 13C NMR, and mass spectra. All the hybrids have been tested for their in vitro anticancer activity against four human cancer cell lines, including HeLa, MCF-7, A549, and PC3. Three of the compounds exhibited remarkable anticancer activity compared to standard drug etoposide. Molecular docking studies with EGFR also strengthened the in vitro anticancer activity.

One-pot Synthesis of Some Novel Xanthine Derived Isoxazoles as Potent Antibacterial Agents

In search of better antibacterial agents, a series of novel xanthine derived 3,5-disubstituted isoxazole derivatives were synthesized (3a-3j) in one-pot using 8-chloro-1,3-dimethyl-7-(prop-2-yn-1-yl)-1H-purine-2,6(3H,7H)-dione and aromatic aldehydes and f

Design, Synthesis and Anticancer Evaluation of New Substituted Thiophene-Quinoline Derivatives

A series of new isoxazolyl, triazolyl and phenyl based 3-thiophen-2-yl-quinoline derivatives were synthesized adopting click chemistry approach. In addition, the synthesis of new useful synthon, (2-chloroquinolin-3-yl) (thiophen-2-yl) methanol, is reported. The obtained compounds were characterized by spectral data analysis and evaluated for their anticancer activity. All the derivatives were subjected to in vitro MTT cytotoxicity screening assay against a panel of four different human cancer cell lines, liver (HepG-2), colon (HCT-116), human cervical cancer (HeLa) and breast (MCF-7). Out of a library of 17 compounds, two compounds have been identified as potent and selective cytotoxic agents against HeLa and MCF-7 cell lines. SAR studies for such hybridized analogues were investigated and phenyl derivatives were proved to be more potent than isoxazole and triazole derivatives. Furthermore, the promising compounds were selected for in vitro inhibition of EGFR-TK and Topo II enzymes. Also, they were subjected to cell cycle arrest analysis and apoptosis assay on MCF-7 cells. Our recent finding highlights these thiophene-quinoline analogues as a promising class of compounds for further studies concerning new anticancer therapies.

Cu(I)-Catalysis of One-Pot Synthesis of Some Novel Regioselective Isoxazole-Benzimidazole Hybrids and Their In Vitro Anti-Cancer Evaluation

Regioselective synthesis of some novel isoxazole-benzimidazole hybrids in high yields via Cu(I)-catalyzed tandem one-pot reaction of aromatic aldehydes with 1-prop-2-ynylbenzimidazole is developed. Structures of the synthesized compounds are confirmed by

Synthesis and biological evaluation of (3-arylisoxazol-5-yl)methyl 6-fluoro-4-oxo-4H-chromene-2-carboxylates as antioxidant and antimicrobial agents

A series of novel (3-arylisoxazol-5-yl)methyl 6-fluoro-4-oxo-4H- -chromene-2-carboxylate derivatives (C1-C12) were synthesized by the Cu(I)- -catalyzed reaction of in situ generated nitrile oxides with prop-2-ynyl 6-fluoro- 4-oxo-4H-chromene-2-carboxylate in good yields and their antioxidant and antimicrobial activities were investigated. Among all the synthesized compounds, C1 (IC50: 16.43±0.57 μM) and C12 (IC50:15.98±0.72 μM) registered good antioxidant activity as compared to the standard drug trolox. Compounds C1, C3 and C6 registered very good inhibition against all the tested Gram-positive and Gram-negative bacterial strains with MIC values ranging from 9.375 to 37.5 μg mL-1. Compounds C7-C11 registered good inhibition against Bacillus subtilis and Staphylococcus aureus with MIC values ranging from 18.75 to 37.5 μg mL-1. Compounds C10 and C11 against Pseudomonas aeroginosa showed more prominent activity than the standard drug penicillin (MIC: 12.5 μg mL-1) with an MIC value of 9.375 μg mL-1 (≈ 1.33-fold more potent than penicillin). Compounds C7-C9 registered good to moderate antifungal activity against the four tested fungal strains with MIC values ranging from 18.75 to 37.5 μg mL-1.

Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex

The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.